drugset
drugset / Trial / NCT00767819

Treatment of Patients With RAD001 With Progressive Sarcoma

NCT00767819 ↗

Phase 2 Completed 71 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this multicenter, three-arm, exact binomial single-stage, phase II trial is to determine the preliminary efficacy and safety of RAD001 in patients with histological evidence of progressive or metastatic bone or soft tissue sarcoma.

Timeline

Start
2008-03-31
Primary completion
2017-05-17
Completion
2017-05-17

Outcome

Missed primary endpoint

registry analysis (superiority test); Arm 1 vs Arm 2 vs Arm 3; p = 0.1 NCT00767819 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule 10 mg Oral

Indications

sarcoma